Plasma alemtuzumab levels in patients with chronic lymphocytic leukemia treated with alemtuzumab combined with chemotherapy reflect the efficacy of the treatment: A hypothesis

Leukemia and Lymphoma

Volumn 54, Issue 4, 2013, Pages 790-793

  Vojdeman, Fie Juhl ^a   Jurlander, Jesper ^a   Veer, Mars Van't ^b   Itälä Remes, Maija ^c   Kimby, Eva ^d   Tjonnfjord, Geir Erland ^e   Walewski, Jan ^f   Kozák, Tomas ^g   Polliack, Aaron ^h   Montagna, Michela ⁱ   Regazzi, Mario ⁱ   Kirkby, Nikolai ^a   Oers, Marinus Van ^j   Geisler, Christian Hartmann ^a  

^a Rigshospitalet   (Denmark)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d KAROLINSKA INSTITUTE   (Sweden)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f INSTITUTE OF ONCOLOGY   (Poland)

^g CHARLES UNIVERSITY   (Czech Republic)

^h HEBREW UNIVERSITY   (Israel)

ⁱ FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^j ACADEMIC MEDICAL CENTER   (Netherlands)

more..

Author keywords

Alemtuzumab; Campath; Chronic lymphocytic leukemia; CLL; Immunochemotherapy; Pharmacokinetics

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; FLUDARABINE;

ARTICLE; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; INDUCTION CHEMOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOPENIA; PROGNOSIS; TREATMENT OUTCOME;

EID: 84878426713     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.720373     Document Type: Article

References (19)

1. Lepretre S, Aurran T, Mahé B, et al. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alem tuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood 2012; 119: 5104-5110.
2. Elter T, James R, Busch R, et al. Fludarabine and cyclophosphamide in combination with alemtuzumab (FCCam) in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia. Leukemia 2012 May 15. [Epub ahead of print]
3. Geisler CH, van ' t Veer MB, van Putten W, et al. Immunochemotherapy with low-dose subcutaneous alemtuzumab (A) plus oral fludarabine and cyclophosphamide (FC) is safe and induces more and deeper complete remissions in untreated patients with high-risk chronic lymphocytic leukemia (CLL) than chemotherapy w ith FC alone. An early analysis of the randomised phase-III trial HOVO N 68 CLL trial. Blood 2011 ;118:(Suppl. 1): Abstract 290.
4. Mould D R, Baumann A, Kuhlmann J, et al. Population pharmacokinetics- pharmacodynamics of alemtuzumab (campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol 2007; 64: 278-291.
5. Hale G, Rebello P, Brettman L R, et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 2004; 104: 948-955.
6. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): A randomised controlled trial. Lancet 2007; 370: 230-239.
7. Flinn I W, Neuberg D S, Grever M R, et al. Phase 3 trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: Us intergroup trial e2997. J Clin Oncol 2007; 25: 793-798.
8. Eichhorst B F, Busch R, Hopfi nger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885-891.
9. Montagna M, Avanzini M A, Visai L, et al. A new sensitive enzymelinked immunosorbent assay (ELISA) for alemtuzumab determination: Development, validation and application. Int J Immunopathol Pharmacol 2007; 20: 363-371.
10. Hallek M, Cheson B D, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
11. Montillo M, Tedeschi A, Miqueleiz S, et al. A lemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 2006; 24: 2337-2342.
12. Elter T. Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia. Haematologica 2009; 94: 150-152.
13. Wierda W G, Kipps T J, Keating M J, et al. Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer 2010; 117: 116-124.
14. Elter T, Molnar I, Kuhlmann J, et al. Pharmacokinetics of alemtuzumab and the relevance in clinical practice. Leuk Lymphoma 2008; 49: 2256-2262.
15. Lin T S, Donohue K A, Byrd J C, et al. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: Fi nal analysis of CALGB 10101. J Clin Oncol 2010; 28: 4500-4506.
16. Riechmann L, Clark M, Waldmann H, et al. Reshaping human antibodies for therapy. Nature 1988; 332: 323-327.
17. Sorror ML, Storer B, Sandmaier BM, et al. Impacts of cytogenetic abnormalities and prior alemtuzumab on outcomes of patients (pts) with high-risk chronic lymphocytic leukemia (CLL) given nonmyeloablative allogeneic hematopoietic cell transplantation (HCT). Blood 2010; 116: (Suppl. 1): Abstract 2364.
18. Ding W, Shanafelt TD, Rabe K, et al. Alemtuzumab use and survival after reduced intensity allogeneic stem cell transplantation in high-risk chronic lymphocytic leukemia (CLL). Blood 2011; 118 :(Suppl. 1): Abstract 4152.
19. Mü ller C, Murawski N, Wiesen MHJ, et al. The role of sex and weight on rituximab clearance and serum elimination half life in elderly patients with DLBCL. Blood 2012; 119: 3276-3284.